Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000102909-25-000074
Filing Date
2025-10-30
Accepted
2025-10-30 14:37:50
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 4558
  Complete submission text file 0000102909-25-000074.txt   6196
Mailing Address PO BOX 2600 V26 VALLEY FORGE PA 19482-2600
Business Address 100 VANGUARD BLVD MALVERN PA 19355 6106691000
VANGUARD GROUP INC (Filed by) CIK: 0000102909 (see all company filings)

EIN.: 231945930 | State of Incorp.: PA | Fiscal Year End: 1231
Type: SCHEDULE 13G/A

Mailing Address 43 THORNDIKE STREET CAMBRIDGE MA 02141
Business Address 43 THORNDIKE STREET CAMBRIDGE MA 02141 617-683-0917
Amylyx Pharmaceuticals, Inc. (Subject) CIK: 0001658551 (see all company filings)

EIN.: 464600503 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-93265 | Film No.: 251434365
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)